Circulating tumour DNA in early stage colorectal cancer: can blood tell all?

Yat Hang To¹, Margaret Lee^{2

3

4}, Peter Gibbs^{2

3

5}, Jeanne Tie^{1

2

3

5}

Affiliations

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
² Division of Systems Biology and Personalised Medicine, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
³ Department of Medical Oncology, Western Health, Victoria, Australia.
⁴ Department of Medical Oncology, Eastern Health, Victoria, Australia.
⁵ Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia.

Editorial

Yat Hang To et al. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S358.

doi: 10.21037/atm.2019.09.55.

Yat Hang To¹, Margaret Lee^{2

3

4}, Peter Gibbs^{2

3

5}, Jeanne Tie^{1

2

3

5}

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
² Division of Systems Biology and Personalised Medicine, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
³ Department of Medical Oncology, Western Health, Victoria, Australia.
⁴ Department of Medical Oncology, Eastern Health, Victoria, Australia.
⁵ Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.
Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, Heilskov Rasmussen M, Vang S, Shchegrova S, Frydendahl Boll Johansen A, Srinivasan R, Assaf Z, Balcioglu M, Olson A, Dashner S, Hafez D, Navarro S, Goel S, Rabinowitz M, Billings P, Sigurjonsson S, Dyrskjøt L, Swenerton R, Aleshin A, Laurberg S, Husted Madsen A, Kannerup AS, Stribolt K, Palmelund Krag S, Iversen LH, Gotschalck Sunesen K, Lin CJ, Zimmermann BG, Lindbjerg Andersen C. Reinert T, et al. JAMA Oncol. 2019 Aug 1;5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528. JAMA Oncol. 2019. PMID: 31070691 Free PMC article.

1. Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-19. 10.1200/JCO.2004.05.063 - DOI - PubMed
1. Saltz LB, Niedzwiceki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25:3456-61. 10.1200/JCO.2007.11.2144 - DOI - PubMed
1. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:3117-25. 10.1200/JCO.2008.21.6663 - DOI - PubMed
1. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012;13:1225-33. 10.1016/S1470-2045(12)70509-0 - DOI - PubMed
1. Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29:11-6. 10.1200/JCO.2010.30.0855 - DOI - PMC - PubMed